Table 2.
Number of treatments received and availability of response data
| Groups | Subgroups | No. of Patients | No. of Treatments | No. of Patients with Response Data | No. of Treatments with Response Data |
|---|---|---|---|---|---|
| Total cohort | 271 | — | — | — | |
| Not receiving ACEi/ARB or intensified immunosuppression (%) | Total | 52 (19) | — | — | — |
| Reason for no ACEi/ARB or intensified immunosuppression | Congenital nephrotic syndrome | 24 | — | — | — |
| CKD/kidney failure at presentation | 13 | — | — | — | |
| Syndromic | 3 | — | — | — | |
| Familial | 1 | — | — | — | |
| No medication data | 11 | — | — | — | |
| Total receiving treatments (%) | ACEi/ARB or intensified immunosuppression | 219/271 (81) | 540 | 202/219 (92) | 480/540 (89) |
| Grouped by patients (%) | ACEi/ARB only | 33/219 (15) | — | — | — |
| Intensified immunosuppression only | 86/219 (39) | — | — | — | |
| ACEi/ARB and intensified immunosuppression | 100/219 (46) | — | — | — | |
| Grouped by treatments (%) | All ACEi/ARB | 133/219 (61) | 160/540 (30) | 112/133 (84) | 134/160 (84) |
| All intensified immunosuppression | 186/219 (85) | 380/540 (70) | 178/186 (96) | 346/380 (91) |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.